M&A
confidence high
sentiment positive
materiality 0.90
Swiftmerge Acquisition Corp. announces $400M merger with HDL Therapeutics
AleAnna, Inc.
- Swiftmerge (IVCP) to acquire HDL Therapeutics in all-stock/cash deal valued at $400M; $10.00 per share valuation.
- Shareholders of HDL to receive up to 11M earnout shares if IVCP stock hits $12.50 or $15.00 VWAP milestones within two years.
- Closing conditions include minimum $30M cash in trust after redemptions, Nasdaq listing, and shareholder approvals; Outside Closing Date March 15, 2024, extendable to June 15, 2024.
- Pre-closing financing of up to $2.68M in 2023 and $3M in 2024 required for certain covenants; lock-up of 6 months post-closing with potential early release if price >= $12.00.
- Board unanimously approved and recommends shareholder vote; Domestication from Cayman Islands to Delaware prior to closing.